Pistoia Alliance USA Conference 2016
-
Upload
pistoia-alliance -
Category
Science
-
view
95 -
download
0
Transcript of Pistoia Alliance USA Conference 2016
![Page 1: Pistoia Alliance USA Conference 2016](https://reader035.fdocuments.us/reader035/viewer/2022062522/587e50181a28abeb1a8b5d43/html5/thumbnails/1.jpg)
— APPLICATION OF MACHINE LEARNING TECHNIQUES TO PATIENT STRATIFICATIONALEXANDER IVLIEV, PHDOCTOBER 2016
—
![Page 2: Pistoia Alliance USA Conference 2016](https://reader035.fdocuments.us/reader035/viewer/2022062522/587e50181a28abeb1a8b5d43/html5/thumbnails/2.jpg)
2
—
Why is it important?Technical definition of the problemExample from our researchExample from published research
01020304
AGENDA
![Page 3: Pistoia Alliance USA Conference 2016](https://reader035.fdocuments.us/reader035/viewer/2022062522/587e50181a28abeb1a8b5d43/html5/thumbnails/3.jpg)
3
—
Why is it important?Technical definition of the problemExample from our researchExample from published research
01020304
AGENDA
![Page 4: Pistoia Alliance USA Conference 2016](https://reader035.fdocuments.us/reader035/viewer/2022062522/587e50181a28abeb1a8b5d43/html5/thumbnails/4.jpg)
4
—CASE STUDY - GEFITINIB
Early stratification would have prevented the withdrawal, but retrospective analysis did allow a new Marketing approval
1st line therapy for metastatic NSCLC with exon 19 deletions or exon 21 (L858R) substitutions
Launched with accelerated
approval
Withdrawn from market after phase III
study
NDA resubmission
with companion diagnostic
• Accelerate approval but post-marketing trial requested for full approval
• Phase III studies showed no improvement in overall survival
• Drug withdrawn from the market• Retrospective data analysis: 10% partial response in genotype unselected patients
>70% responders have activating mutations in EGFR
Best responses seen in East Asians, females and non-smokers
• NDA resubmitted with narrowed labelling and mutation-based companion diagnostic
• Unfortunately, lost market share to Tarceva during elucidation of patient segment
![Page 5: Pistoia Alliance USA Conference 2016](https://reader035.fdocuments.us/reader035/viewer/2022062522/587e50181a28abeb1a8b5d43/html5/thumbnails/5.jpg)
5
—TECHNICAL DEFINITION OF THE PROBLEM
Patients
Gene
s
Class 1,Disease type 1
Class 2,Disease type 2
Class ?
Patient
![Page 6: Pistoia Alliance USA Conference 2016](https://reader035.fdocuments.us/reader035/viewer/2022062522/587e50181a28abeb1a8b5d43/html5/thumbnails/6.jpg)
6
—AIM: TO DISCOVER PATIENT SELECTION BIOMARKERS FOR ERLOTINIB USING PRECLINICAL DATA SUCH AS CELL LINE
VIABILITY SCREENS
Clinical trial design for erlotinib
Gene expression240 cell lines
Sensitive Resistant
+
![Page 7: Pistoia Alliance USA Conference 2016](https://reader035.fdocuments.us/reader035/viewer/2022062522/587e50181a28abeb1a8b5d43/html5/thumbnails/7.jpg)
7
—INTEGRATED BIOMARKER DISCOVERY APPROACH
Statistical approaches
Pathway knowledgePathway-driven
approaches
![Page 8: Pistoia Alliance USA Conference 2016](https://reader035.fdocuments.us/reader035/viewer/2022062522/587e50181a28abeb1a8b5d43/html5/thumbnails/8.jpg)
8
—MACHINE LEARNING WORKFLOW
54,675 probesets
3,787 probesets
485 genes
191 genes
51 genes
![Page 9: Pistoia Alliance USA Conference 2016](https://reader035.fdocuments.us/reader035/viewer/2022062522/587e50181a28abeb1a8b5d43/html5/thumbnails/9.jpg)
9
—
ClinicalTrials.gov numbers: NCT00409968, NCT00411671, NCT00411632, NCT00410059, NCT00410189
![Page 10: Pistoia Alliance USA Conference 2016](https://reader035.fdocuments.us/reader035/viewer/2022062522/587e50181a28abeb1a8b5d43/html5/thumbnails/10.jpg)
10
—VALIDATION: INDEPENDENT CLINICAL TRIAL
Thanks to Bin Li at Takeda for slide
![Page 11: Pistoia Alliance USA Conference 2016](https://reader035.fdocuments.us/reader035/viewer/2022062522/587e50181a28abeb1a8b5d43/html5/thumbnails/11.jpg)
11
—VALIDATION: INDEPENDENT CLINICAL TRIAL
Thanks to Bin Li at Takeda for slide
![Page 12: Pistoia Alliance USA Conference 2016](https://reader035.fdocuments.us/reader035/viewer/2022062522/587e50181a28abeb1a8b5d43/html5/thumbnails/12.jpg)
12
—BIOLOGICAL INTERPRETATION
Network Building Algorithms
Analyze networkAnalyze network (transcription factors)Analyze network (receptors)Transcription regulationShortest pathsTrace pathwaysSelf regulationDirect interactionsAuto expandExpand by one interactionManual expand
![Page 13: Pistoia Alliance USA Conference 2016](https://reader035.fdocuments.us/reader035/viewer/2022062522/587e50181a28abeb1a8b5d43/html5/thumbnails/13.jpg)
13
—
Why is it important?Technical definition of the problemExample from our researchPublished research: community effort
01020304
AGENDA
![Page 14: Pistoia Alliance USA Conference 2016](https://reader035.fdocuments.us/reader035/viewer/2022062522/587e50181a28abeb1a8b5d43/html5/thumbnails/14.jpg)
14
—MAQC CONSORTIUM
Leming Shi et al. MAQC-II study of common practices for the development and validationof microarray-based predictive models. Nat. Biotech., 2010
• 6 datasets• 13 endpoints• 36 data analysis teams• 30,000 models
![Page 15: Pistoia Alliance USA Conference 2016](https://reader035.fdocuments.us/reader035/viewer/2022062522/587e50181a28abeb1a8b5d43/html5/thumbnails/15.jpg)
15
—LESSONS LEARNED
The number one factor which predicts how accurate predictions will be is endpoint complexity
Leming Shi et al. MAQC-II study of common practices for the development and validationof microarray-based predictive models. Nat. Biotech., 2010
It’s easy to tell boys from girls
It’s hard to predict outcome of cancer treatment
![Page 16: Pistoia Alliance USA Conference 2016](https://reader035.fdocuments.us/reader035/viewer/2022062522/587e50181a28abeb1a8b5d43/html5/thumbnails/16.jpg)
16
—LESSONS LEARNED
Leming Shi et al. MAQC-II study of common practices for the development and validationof microarray-based predictive models. Nat. Biotech., 2010
“The top-performing teams were mainly industrial participants with many years of experience in microarray data analysis, whereas bottom-performing teams were mainly less-experienced graduate students or researchers.”
![Page 17: Pistoia Alliance USA Conference 2016](https://reader035.fdocuments.us/reader035/viewer/2022062522/587e50181a28abeb1a8b5d43/html5/thumbnails/17.jpg)
17
—LESSONS LEARNED
Leming Shi et al. MAQC-II study of common practices for the development and validationof microarray-based predictive models. Nat. Biotech., 2010
“Applying good modeling practices appeared to be more important than the actual choice of a particular algorithm.”
“Many models with similar performance can be developed from a given data set.”
![Page 18: Pistoia Alliance USA Conference 2016](https://reader035.fdocuments.us/reader035/viewer/2022062522/587e50181a28abeb1a8b5d43/html5/thumbnails/18.jpg)
18
—
Thank you for your attention